Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neus Llarch

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Seminars in Liver Disease|February 27, 2026
Optimizing Liver Cancer Care Through BCLC PrinciplesGemma Iserte, Neus Llarch, Andrew M Moon, et al.
Current Opinion in Pharmacology|August 21, 2021
Current pharmacological treatment of hepatocellular carcinomaSergio Muñoz-Martínez, Gemma Iserte, Marco Sanduzzi-Zamparelli, et al.
European Radiology|July 2, 2020
Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acidJordi Rimola, Anna Darnell, Ernest Belmonte, et al.
Hepatology (Baltimore, Md.)|June 22, 2013
Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial designMaria Reig, Jordi Rimola, Ferran Torres, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 12, 2019
Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules ≤2 cm in cirrhosisCarmen Ayuso, Alejandro Forner, Anna Darnell, et al.
Journal of Hepatology|April 8, 2014
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenibMaria Reig, Ferran Torres, Carlos Rodriguez-Lope, et al.
Hepatology (Baltimore, Md.)|January 12, 2023
Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysisIsmael El Hajra, Marco Sanduzzi-Zamparelli, Víctor Sapena, et al.
Alimentary Pharmacology & Therapeutics|January 30, 2019
Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenibÁlvaro Díaz-González, Marco Sanduzzi-Zamparelli, Víctor Sapena, et al.
European Radiology|August 3, 2019
Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinomaJordi Rimola, Alejandro Forner, Víctor Sapena, et al.
Cancers|January 27, 2021
Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular CarcinomaJosep Corominas, Victor Sapena, Marco Sanduzzi-Zamparelli, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Seminars in Liver Disease|February 27, 2026
Optimizing Liver Cancer Care Through BCLC PrinciplesGemma Iserte, Neus Llarch, Andrew M Moon, et al.
Current Opinion in Pharmacology|August 21, 2021
Current pharmacological treatment of hepatocellular carcinomaSergio Muñoz-Martínez, Gemma Iserte, Marco Sanduzzi-Zamparelli, et al.
European Radiology|July 2, 2020
Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acidJordi Rimola, Anna Darnell, Ernest Belmonte, et al.
Hepatology (Baltimore, Md.)|June 22, 2013
Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial designMaria Reig, Jordi Rimola, Ferran Torres, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 12, 2019
Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules ≤2 cm in cirrhosisCarmen Ayuso, Alejandro Forner, Anna Darnell, et al.
Journal of Hepatology|April 8, 2014
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenibMaria Reig, Ferran Torres, Carlos Rodriguez-Lope, et al.
Hepatology (Baltimore, Md.)|January 12, 2023
Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysisIsmael El Hajra, Marco Sanduzzi-Zamparelli, Víctor Sapena, et al.
Alimentary Pharmacology & Therapeutics|January 30, 2019
Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenibÁlvaro Díaz-González, Marco Sanduzzi-Zamparelli, Víctor Sapena, et al.
European Radiology|August 3, 2019
Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinomaJordi Rimola, Alejandro Forner, Víctor Sapena, et al.
Cancers|January 27, 2021
Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular CarcinomaJosep Corominas, Victor Sapena, Marco Sanduzzi-Zamparelli, et al.
Pageof 3